Every 10-Q that INTL STEM CELL CORP (ISCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ISCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISCO filings page.
International Stem Cell Corporation reported Q2 2026 product sales of $2.7 million, up 9% year over year, driven mainly by biomedical media sales. Six‑month product sales rose to $5.0 million. Despite this, the company posted a Q2 net loss of $71 thousand and a six‑month net loss of $291 thousand, with profit margins easing as sales mix shifted and skin‑care margins normalized.
Total assets were $5.1 million at June 30, 2026, including cash of $1.1 million, against current liabilities of $5.0 million and a related‑party note payable of $3.3 million. Accumulated deficit reached $111.4 million, and management stated there is substantial doubt about the ability to continue as a going concern without new financing or maturity extensions.
Subsequent to quarter‑end, the company agreed to sell 100% of its Lifeline Cell Technology subsidiary to ATCC for $25.0 million in cash, subject to working‑capital and other customary adjustments, with $2.6 million placed in escrow at closing. One biomedical customer accounted for 61% of Q2 consolidated product sales, underscoring significant customer concentration risk.
International Stem Cell Corporation reported product sales of $2.3 million for the quarter ended March 31, 2026, up from $2.1 million a year earlier, driven mainly by its biomedical segment and modest growth in skin care products. Cost of sales fell, lifting gross margin to 59% from 53%, while operating expenses increased, particularly legal and consulting fees. The company posted a net loss of $0.2 million and ended the quarter with $0.9 million in cash and a related-party note payable of $2.35 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new financing or extensions of existing debt.
International Stem Cell Corporation reported Q3 2025 results. Product sales were $2.369 million, up from $2.179 million a year ago, and income from operations was $94 thousand versus a prior loss. Net income was $57 thousand compared with a net loss of $125 thousand in Q3 2024.
Cash was $966 thousand at quarter-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional financing or extensions of existing financing. A related party note payable is presented at $3.305 million within current liabilities, and its maturity was extended to September 15, 2026.
Sales were led by the biomedical segment (LCT) with $2.204 million; the skin care segment (LSC) contributed $165 thousand. One customer accounted for 54% of consolidated product sales in the quarter and 62% of accounts receivable as of September 30, 2025. Basic and diluted EPS were $0.00, with 8,004,389 weighted-average shares.